FDA, CDC experts: What physicians need to know about tecovirimat (TPOXX) for treatment of monkeypox, Part 1

Experts from the AMA, FDA and CDC discuss tecovirimat, or TPOXX, for the treatment of monkeypox in infected individuals. The discussion provides background on tecovirimat, including its current status, availability and access while the drug is under an investigational new drug application. Guests include Adam Sherwat, MD, Deputy Director, Office of Infectious Disease at FDA’s Center for Drug Evaluation and Research; Brett W. Petersen, MD, MPH, Deputy Chief, Poxvirus and Rabies Branch, CDC’s Division of High-Consequence Pathogens and Pathology; and Timothy Wilkin, MD, MPH, Professor of Medicine and Assistant Dean for Clinical Research Compliance for Human Research Protections at Weill Cornell Medicine and TPOXX clinical trial lead.    ⭐⭐⭐⭐⭐ 📺 Follow the AMA on YouTube: @americanmedicalassociation  🎥 Watch #AMAUpdate for the latest in health care news for physicians: https://bit.ly/AMA_Update 📧 Subscribe to AMA Morning Rounds newsletter, with the news you need every morning delivered to your inbox: https://bit.ly/AMA-MorningRounds 🎧 Listen to our latest podcast episodes now: https://bit.ly/AMA_Podcasts 📲 Download AMA Connect for news, podcasts, video updates and learning in one place: https://apple.co/3URzNES